Bionano Genomics stocks rose by over 14% ($0.81) yesterday, and our robots were quick to spot this opportunity, generating more than a 10% profit on this stock in just one day. We'd like to highlight our Swing Trader Volatility Balanced Strategy v2 TA robot, which is gaining momentum once again.
Introducing our AI robot - the perfect solution for traders seeking a balanced strategy. This advanced technology opens no more than 30 trades at a time, with an average duration of 2 days. We have carefully selected a set of stocks with high and medium volatility, giving traders the flexibility to adjust the algorithms for opening trades based on market activity.
Here's how our AI robot works: it first evaluates short- and medium-term trends for each stock using complex algorithms. Then, using a proprietary set of technical indicators, it looks for a signal to open a trade. Finally, based on the volatility and direction of both types of trends, a separate algorithm determines the position size to be opened.
Once a trade is entered, our AI robot places an order for "Take Profit," with the distance depending on the current market volatility. It uses a stop loss of 3% of the position opening price and a flexible trailing stop to exit positions, enabling traders to save most of the profit if the market reverses.
The robot's trading results are displayed without using margin. To view the full trading statistics and equity chart, click on the "Show More" button on the robot page. Traders can watch live as our AI robot selects equities, enters and exits paper trades on the "Open Trades" tab, while the "Closed Trades" tab provides a complete record of all previous trades made by our AI robot.
To maximize profits, we recommend subscribing to several robots at once. Good luck with your trading!
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where BNGO advanced for three days, in of 225 cases, the price rose further within the following month. The odds of a continued upward trend are .
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BNGO's RSI Oscillator exited the oversold zone, of 49 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on July 02, 2025. You may want to consider a long position or call options on BNGO as a result. In of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for BNGO just turned positive on July 02, 2025. Looking at past instances where BNGO's MACD turned positive, the stock continued to rise in of 39 cases over the following month. The odds of a continued upward trend are .
BNGO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BNGO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for BNGO entered a downward trend on July 09, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.597) is normal, around the industry mean (24.348). P/E Ratio (0.000) is within average values for comparable stocks, (77.706). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (0.993) is also within normal values, averaging (42.660).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. BNGO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BNGO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of technologies for analysis of large biological molecules
Industry MedicalSpecialties